CatalYm: opening up tumors to immune cells

CatalYm is targeting a lesser known immunosuppressant function of GDF15 to resensitize cancer patients to checkpoint blockade and enhance the ability of CAR T therapies to infiltrate solid tumors.

The Munich-based biotech has raised €50 million ($58.2 million) in a series B round led by Vesalius Biocapital III to bring lead program CTL-002 into a large Phase I trial to treat multiple solid tumors...